Guggenheim将Verve治疗药物的价格目标提高到24美元, 提升基因编辑库存的前景。 Guggenheim raises Verve Therapeutics' price target to $24, upgrading outlook on gene editing stock.

Guggenheim将抗逆转录病毒疗法(VERV)的价格目标提升至24美元, Guggenheim raised its price target for Verve Therapeutics (VERV) to $24, up from $18, maintaining a "buy" rating. Verve治疗技术开发心血管疾病基因编辑药品,其主要产品VERVE-101针对肝脏中的PCSK9基因。 Verve Therapeutics develops gene editing medicines for cardiovascular diseases, with its lead product VERVE-101 targeting the PCSK9 gene in the liver. 股票的平均“Buy”评级为26.33美元,一致商定价格目标为26.33美元。 The stock has an average "Buy" rating and a consensus price target of $26.33. Cantor Fitzgerald也提升VERV为“超重”评级。 Cantor Fitzgerald also upgraded VERV to an "overweight" rating.